ITN (Innovative Training Network)

Predict is funded by the Marie Skłodowska-Curie Actions, part of the EU’s Horizon 2020 Programme. Grant Agreement No 766276.

01/10/2017 – 30/09/2021 (4 years)

Maastricht University


Fondazione IRCCS Istituto Nazionale dei Tumori

Université de Liège

Erasmus University Medical Centre Rotterdam

Deutsches Krebsforschungszentrum Heidelberg

Institut National de la Santé et de la Recherche Médicale


Mirada Medical LTD

Perspectum Diagnostics LTD

Health Innovation Ventures BV


Elsevier BV

European Cancer Patient Coalition (ECPC)

Ttopstart BV


Università Cattolica S. Cuore, Rome

Universitatsklinikum Heidelberg

Heidelberg Ion Beam Therapy Center GMBH

Why it matters

Tumour cells can differ greatly both between patients (inter-tumour heterogeneity) and within patients (intra-tumour heterogeneity). These differences affect how patients respond to cancer therapy and hamper wide deployment of personalised medicine for cancer treatment. PREDICT educates 15 Early Stage Researchers (ESRs) in the fields of radiomics and personalised medicine, training them to analyse large amounts of radiographic images to determine tumour heterogeneity and predict how patients will respond to treatment.

What ECPC does

ECPC provides the Early Stage Researchers with training courses and workshops on communicating complex research results to a public audience, understanding the patient perspective, and scientific writing. ECPC uses its communication channels to share information about the project, its results and its participants. ECPC is represented on the Project Advisory Board to monitor project progress and provide input on the design and overall direction.

EU flag logo

This project is funded by the European Union